Welcome to BioSeeker Group!

Triple Analysis: Melanoma, Pancreatic Cancer and Peptides

Additional Information

Published Date Jun 12, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3297
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Melanoma, Pancreatic Cancer and Peptides in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the compound strategy of Peptides.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Pancreatic Cancer and Peptides.

    To find out more about Triple Analysis: Melanoma, Pancreatic Cancer and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Pancreatic Cancer and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Melanoma and Pancreatic Cancer and by the compound strategy of Peptides. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Melanoma
The melanoma drug report part comprises defined and up to date development strategies for 282 drugs within the portfolio of 164 companies world-wide, from Ceased to Marketed. The report extensively analyses their 226 identified drug targets, organized into 187 drug target strategies, and assesses them in melanoma.
This part is based on the following publication:
Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

Part II: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part III: Peptides
The peptide drug report part comprises defined and up to date development strategies for 171 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 132 identified drug targets, organized into 109 drug target strategies, and assesses them in 62 cancer indications.
This part is based on the following publication:
Cancer Peptides: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Melanoma
5.1 The Scope of this Report 26
6 Consider the Therapeutic Target Among Melanoma Drugs for the Highest Therapeutic Outcome and Return on Investment (226 Drug Targets) 30-467
7 First-in-Class and Me-too Analysis of Melanoma Drugs (187 Drug Target Strategies and 282 Drugs) 468-677
8 Is First-in-Class the Best-in-Class? 488-678
9 Compound Strategies at Work: Competitive Benchmarking of Melanoma Drugs by Compound Strategy (7 Compound Strategies) 679-710
10 The Competition Through Close Mechanistic Approximation of Melanoma Drugs 711
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Melanoma Drug Pipeline by Company (164 Companies and 282 Drugs) 716-1165
12 Disclaimer 1166
Figures: Includes 5 Figures
Tables: Includes 222 Tables
Total Number of Pages: 1,181

Part II: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part III: Peptides
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Peptide Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (132 Drug Targets) 31-252
7 First-in-Class and Me-too Analysis of Peptide Drugs in Cancer (109 Drug Target Strategies and 171 Drugs) 253-267
8 Is First-in-Class the Best-in-Class? (109 Drug Target Strategies and 171 Drugs) 268-387
9 The Competition through Close Mechanistic Approximation of Peptide Drugs in Cancer 388
10 Selecting Indication for Peptide Drugs in Oncology ( 62 Cancer Indications) 391-475
11 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Peptide Drug Pipeline by Investigator (114 Investigators and 171 Drugs) 476-1001
12 Disclaimer 1002
Figures: Includes 5 Figures
Tables: Includes 232 Tables
Total Number of Pages: 1,013

This Report Includes the Following Companies:
3SBio
7TM Pharma
AB Science
Abbott
AbbVie
Abiogen
Acceleron Pharma
Actelion
Active Biotech
Adherex
Advanced Life Sciences
Advantagene
Advaxis
AEgera
AEterna Zentaris
Affymax
Agenus
Aida Pharmaceuticals
Aileron Therapeutics
Allostera
Allosterix
Alnylam
AlphaVax
Altor BioScience
Ambit Biosciences
Ambrilia Biopharma
Amgen
Anchor Therapeutics
AngioChem
Angstrom Pharmaceuticals
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
AplaGen Biopharmaceuticals
Apogee Biotechnology
ApopLogic Pharmaceuticals
Apotex
Ardana
Ardea Biosciences
Ariad
ArQule
Array BioPharma
Astellas
Astex Pharmaceuticals
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Baxter International
Bayer
Betapharma
Bio-Medisinsk Innovasjon
BioAlliance Pharma
Biogen Idec
Biokine Therapeutics
Bionovo
BioNTech
BioNumerik
BioSante
Biosceptre
Biotech Ltd
Biotecnol
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Camurus
CanBas
Cancer Advances
Cancer Innovations
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celsion
Celtic Pharma
Center of Molecular Immunology
CG Therapeutics
Chemokine Therapeutics
Chiasma
CJ Corp
Clavis Pharma
Cleveland BioLabs
Clinuvel
CompleGen
Compugen
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CritiTech
CSL
Curaxis
CureTech
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dara Biosciences
Debiopharm
Deciphera Pharmaceuticals
Dendreon
Digna Biotech
DNAVEC
Dong-A
Dongkook Pharm
EGEN Inc
Eisai
Eli Lilly
Endo Pharmaceuticals
Enkam Pharmaceuticals
EntreMed
Enzon
Epeius Biotechnologies
EpiCept
Esperance Pharmaceuticals
Exelixis
FibroGen
Flamel Technologies
Formula Pharmaceuticals
Galectin Therapeutics
Galena Biopharma
Generex
Genmab
GENova Biotherapeutics
Genovax
Genta
GenVec
Geron
GlaxoSmithKline
Glide Pharma
Gliknik
GlycoGenesys
GP Pharm
Gradalis
Gryphon Therapeutics
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
Innovive
Inotek
Inovio
Insmed
Insys Therapeutics
Intas Biopharmaceuticals
Intracel
Intrexon
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Jennerex Biotherapeutics
Johnson & Johnson
Kadmon
KAEL-GemVax
Kalypsys
Karyon-CTT
Kiadis
Kirax
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
LG Life Sciences
Ligand
Lipotek
Mannkind
Marillion Pharmaceuticals
MBiotec
Meda
MediGene
Mediolanum
Medisyn Technologies
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
Mochida
Mojave Therapeutics
MolMed
Mologen
Nektar Therapeutics
Nemod Biotherapeutics
Nereus Pharmaceuticals
Neurobiological Technologies
Nidus Laboratories
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Novacea
NovaLead
Novartis
Novogen
NPS Pharmaceuticals
Oasmia
Oncalis
OncoMed
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Oxford BioMedica
OXiGENE
Pacific Biotech
Paladin Labs
PanaGin
Patrys
PBL Therapeutics
Pepscan Therapeutics
Peptagen
PepTx
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
PhiloGene
Pierre Fabre
Piramal
Progen
ProMetic Life Sciences
Protagonist
Protgen
Q Chip
QLT
Raptor Pharmaceutical
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
Reliance Life Sciences
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Santaris Pharma
Santhera Pharmaceuticals
Sarepta Therapeutics
Sareum
Scancell
SciClone Pharmaceuticals
Seattle Genetics
Serometrix
Shire
Simcere Pharmaceuticals
Solbec Pharmaceuticals
Soligenix
Spectrum Pharmaceuticals
Spirogen
Sunesis
SuperGen
Swedish Orphan Biovitrum
Synta Pharmaceuticals
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Targa Therapeutics
Targepeutics
Tau Therapeutics
Teva
Thallion Pharmaceuticals
Therion Biologics
Theryte
Titan Pharmaceuticals
to-BBB
Tolerx
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trion Pharma
UMN Pharma
Unigene
United Biomedical
Vaxil BioTherapeutics
Vaxon Biotech
VaxOnco
VBL Therapeutics
Vectura
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
ViroMed
WntResearch
Xerion
Xigen
Yakult Honsha
YM BioSciences
York Pharma
Zelos Therapeutics
Zensun
Zeria
A Shortlist of Drugs Included are:
A6
abarelix
ABT-510
AEB071
AEG-35156
AEZS-108
afamelanotide
aflibercept
agatolimod
AGS-1C4D4
aldesleukin
ALT-801
angiopep+paclitaxel
APO-866
apricoxib
ARC-100
ARQ-197
ARRY-438162
astuprotimut-r
Auto TAG vaccine
axitinib
bardoxolone methyl
belinostat
bevacizumab
BMS-663513
BMS-936558
bortezomib
bosutinib
brivanib alaninate
brivudine
Buparlisib
Cabozantinib
capecitabine
catumaxomab
CB-10-01
CBP-501
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
conatumumab
corticorelin acetate
cositecan
CPI-613
CRLX-101
CT-011
dalotuzumab
dasatinib
decitabine
denenicokin
denileukin diftitox
deslorelin
dinaciclib
docetaxel
dovitinib lactate
doxorubicin
E-75
E-7820
E7449
EMD-273063
emepepimut-S
endostatin
eniluracil
entinostat
enzastaurin hydrochloride
EP-100
epirubicin
erlotinib
everolimus
Exherin
FPI-01
fresolimumab
ganetespib
ganitumab
gefitinib
glembatumumab vedotin
golvatinib
goserelin
GSK-1120212
GSK-2118436
GV-1001
GVAX
GX-301
Her-2/Neu peptides
Hi-8 MEL
histamine dihydrochloride
histrelin
icotinib hydrochloride
imatinib mesilate
imMucin
IMP-321
INCB-24360
interferon
interleukin-12
interleukin-2
intetumumab
IPH-1101
ipilimumab
IPP-204106
irinotecan
irinotecan hydrochloride
ISA-P53-01
ispinesib mesylate
JX-594
kahalalide F
KD032
L19-IL2
Lambrolizumab
lanreotide
lapatinib ditosylate
LEE-011
lenvatinib
lestaurtinib
leukemia vaccine
leuprolide
leuprolide acetate
leuprorelin
LGX818
LipoVIL12
masitinib
MDX-1379
MetXia
MGN-1601
MKC-1
MKC-1106-MT
mocetinostat
MORAb-004
motexafin gadolinium
nadroparin
NAFB001
netupitant
nilotinib
nimotuzumab
oblimersen sodium
octreotide
octreotide, LAR
olaparib
OncoVAX
OTS-102
ozarelix
P-276-00
P276-00
paclitaxel
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
peginterferon alfa-2b
pemetrexed disodium
pentamidine isethionate
perifosine
pimasertib
plitidepsin
poly-ICLC
polyclonal antibody stimulator
PX-12
RAF-265
ramucirumab
retaspimycin
Rexin-G
rhIFN-alpha
ridaforolimus
rindopepimut
rintatolimod
romidepsin
romurtide
RX-0201
sagopilone
sargramostim
SCIB-1
selumetinib
siltuximab
sorafenib tosylate
sotatercept
ß-lapachone
sunitinib malate
Survivac
talminogene laherparepvec
tegafur + uracil
temsirolimus
tesetaxel
thalidomide
thymalfasin
tigatuzumab
TM-30339
tocilizumab
trabedersen
trastuzumab
tremelimumab
triciribine phosphate
TS-1
tucotuzumab celmoleukin
vapreotide, immediate-release
varlitinib
velimogene aliplasmid
veliparib
vemurafenib
verubulin
vinflunine ditartrate
vismodegib
vitespen
volociximab
VX-001
WX-671
YM-155
Z-360
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Melanoma, Pancreatic Cancer and Peptides.
    To find out more about Triple Analysis: Melanoma, Pancreatic Cancer and Peptides, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Melanoma, Pancreatic Cancer and Peptides is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Leukemia and Melanoma
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer, Leukemia and Melanoma. Learn More


Triple Analysis: Breast Cancer, Prostate Cancer and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Prostate Cancer and by the mechanism/target/effect of Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


IL-9 Signaling Pathway in Oncology Drug Pipeline Update
BioSeeker Group have identified 83 companies plus partners who are today developing 88 IL-9 pathway targeting drugs in 366 developmental projects in cancer across 67 different targets. In addition, there is 1 suspended drug and another 35 drugs where development has been ceased. Learn More


Triple Analysis: Melanoma, Angiogenesis and Antibodies
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Melanoma), one mechanism/target/effect area (Angiogenesis) and one compound specific area (Antibodies). Learn More